Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Pharma Cracking The U.S. Market Via Reverse Mergers Draw Attention From Authorities

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - A number of Chinese companies publicly traded in the U.S., including several in the pharmaceutical space, have come under the spotlight in the last 18 months after getting to market through reverse mergers
Advertisement

Related Content

Does Two Make A Trend? 3SBio Joins U.S.-listed Chinese Firms Going Private
Will WuXi Benefit From Rival ShangPharma Going Private?
Facing Potential Shareholder Suit And SEC Inquiry In U.S., China Sky One Medical Tries To Reassure Investors
Facing Potential Shareholder Suit And SEC Inquiry In U.S., China Sky One Medical Tries To Reassure Investors
Advertisement
UsernamePublicRestriction

Register

SC078371

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel